<?xml version="1.0" encoding="UTF-8"?>
<!-- generated by CLiX/Wiki2XML [MPI-Inf, MMCI@UdS] $LastChangedRevision: 92 $ on 16.04.2009 15:45:32[mciao0828] -->
<!DOCTYPE article SYSTEM "../article.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink">
<disease  confidence="0.9508927676800064" wordnetid="114070360">
<header>
<title>Complex regional pain syndrome</title>
<id>56283</id>
<revision>
<id>243591658</id>
<timestamp>2008-10-07T04:59:16Z</timestamp>
<contributor>
<username>Bysmuth</username>
<id>6945498</id>
</contributor>
</revision>
<categories>
<category>Neurological disorders</category>
<category>Uncategorized pages needing expert attention</category>
<category>Pages needing expert attention</category>
</categories>
</header>
<bdy>
<template>
<name>Infobox_Disease</name>
<parameters>
<DiseasesDB_mult>
<weblink xlink:type="simple" xlink:href="http://www.diseasesdatabase.com/ddb16345.htm">
16345</weblink></DiseasesDB_mult>
<Name>
Complex regional pain syndrome</Name>
<eMedicineTopic>
123</eMedicineTopic>
<MeshID>
D020918</MeshID>
<DiseasesDB>
12635</DiseasesDB>
<ICD10>
<link xlink:type="simple" xlink:href="../300/3530300.xml">
M</link><weblink xlink:type="simple" xlink:href="http://www.who.int/classifications/apps/icd/icd10online/?gm86.htm+m890">
89.0</weblink>, <link xlink:type="simple" xlink:href="../352/3530352.xml">
G</link><weblink xlink:type="simple" xlink:href="http://www.who.int/classifications/apps/icd/icd10online/?gg50.htm+g564">
56.4</weblink></ICD10>
<eMedicineSubj>
pmr</eMedicineSubj>
<ICD9>
<weblink xlink:type="simple" xlink:href="http://www.icd9data.com/getICD9Code.ashx?icd9337.21">
337.21</weblink>, <weblink xlink:type="simple" xlink:href="http://www.icd9data.com/getICD9Code.ashx?icd9337.22">
337.22</weblink>, <weblink xlink:type="simple" xlink:href="http://www.icd9data.com/getICD9Code.ashx?icd9354.4">
354.4</weblink>, <weblink xlink:type="simple" xlink:href="http://www.icd9data.com/getICD9Code.ashx?icd9355.71">
355.71</weblink></ICD9>
</parameters>
</template>


<table class="metadata plainlinks ambox ">
<row>
<col>

ambox-content" style=""</col>
</row>
<row>
<col class="mbox-image"><p>

<image width="40x40px" src="Ambox_content.png">
</image>
</p>
</col>
<col style="" class="mbox-text">
 <b>This article is in need of attention from an expert on the subject.</b>
Please help recruit one or <weblink xlink:type="simple" xlink:href="http://localhost:18088/wiki/index.php?title=Complex_regional_pain_syndrome&amp;action=edit">
improve this article</weblink> yourself. See the  for details.Please consider using  to associate this request with a </col>
</row>
</table>


<p>

<b>Complex Regional Pain Syndrome</b> (CRPS) is a chronic progressive disease characterized by severe pain, swelling and changes in the skin. The <weblink xlink:type="simple" xlink:href="http://www.iasp-pain.org/">
International Association for the Study of Pain</weblink> has divided CRPS into two types based on the presence of nerve lesion following the injury. </p>
<p>

<list>
<entry level="1" type="bullet">

 Type I, also known as <b>Reflex Sympathetic Dystrophy</b> (RSD), Sudeck's atrophy, <link>
Reflex Neurovascular Dystrophy</link> (RND) or Algoneurodystrophy, does not have  demonstrable nerve lesions.</entry>
<entry level="1" type="bullet">

 Type II, also known as <b>Causalgia</b>, has evidence of obvious nerve damage. </entry>
</list>
</p>
<p>

The cause of this syndrome is currently unknown. Precipitating factors include illness, injury and surgery, although there are documented cases that have no documentable injury to the original site.</p>

<sec>
<st>
History and nomenclature</st>
<p>

The condition currently known as CRPS was originally described by <physical_entity wordnetid="100001930" confidence="0.8">
<communicator wordnetid="109610660" confidence="0.8">
<person wordnetid="100007846" confidence="0.8">
<medical_practitioner wordnetid="110305802" confidence="0.8">
<causal_agent wordnetid="100007347" confidence="0.8">
<health_professional wordnetid="110165109" confidence="0.8">
<adult wordnetid="109605289" confidence="0.8">
<writer wordnetid="110794014" confidence="0.8">
<professional wordnetid="110480253" confidence="0.8">
<doctor wordnetid="110020890" confidence="0.8">
<link xlink:type="simple" xlink:href="../456/853456.xml">
Silas Weir Mitchell</link></doctor>
</professional>
</writer>
</adult>
</health_professional>
</causal_agent>
</medical_practitioner>
</person>
</communicator>
</physical_entity>
 during the <conflict wordnetid="100958896" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../863/863.xml">
American Civil War</link></conflict>
, who is sometimes also credited for inventing the name "causalgia."  However, this term was actually coined by Mitchell's friend Robley Dunglison from the Greek words for heat and for pain.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%221%22])">1</ref>  In the 1940s, the term reflex sympathetic dystrophy came into use to describe this condition, based on the theory that sympathetic hyperactivity was involved in the pathophysiology.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%222%22])">2</ref> Misuse of the terms, as well as doubts about the underlying pathophysiology, led to calls for better nomenclature. In 1993, a special consensus workshop held in Orlando, Florida, provided the umbrella term "complex regional pain syndrome," with causalgia and RSD as subtypes.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%223%22])">3</ref></p>
<p>

<image location="right" width="150px" src="severe_CRPS.jpg" type="thumb">
<caption>

severe CRPS of right arm
</caption>
</image>
</p>

</sec>
<sec>
<st>
Pathophysiology</st>
<p>

The <link xlink:type="simple" xlink:href="../302/598302.xml">
pathophysiology</link> of CRPS is not fully understood. “Physiological wind-up” and central nervous system (CNS) sensitization, are key neurologic processes that appear to be involved in the induction and maintenance of CRPS.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%224%22])">4</ref> There is compelling evidence that the N-methyl-D-aspartate (NMDA) receptor has significant involvement in the CNS sensitization process.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%225%22])">5</ref> It is also hypothesized that elevated CNS glutamate levels promote "physiological wind-up" and CNS sensitization.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%224%22])">4</ref> In addition, there is experimental evidence that demonstrates NMDA receptors in peripheral nerves.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%226%22])">6</ref> Because immunological functions can modulate CNS physiology, it has also been hypothesized that a variety of immune processes may contribute to the initial development and maintenance of peripheral and central sensitization.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%227%22])">7</ref><ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%228%22])">8</ref> Furthermore, trauma related cytokine release, exaggerated neurogenic inflammation, sympathetic afferent coupling, adrenoreceptor pathology, glial cell activation, cortical reorganisation,<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%229%22])">9</ref> and <link xlink:type="simple" xlink:href="../313/66313.xml">
oxidative</link> damage (e.g. by <link xlink:type="simple" xlink:href="../028/235028.xml">
free radicals</link>) are all concepts that have been implicated in the pathophysiology of CRPS.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2210%22])">10</ref></p>


</sec>
<sec>
<st>
Susceptibility</st>
<p>

CRPS can strike at any age, but the mean age at diagnosis is 42,  the most common duration of the condition is 2 to 6 months <ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2211%22])">11</ref>. CRPS has been diagnosed in children as young as 2 years old <ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2212%22])">12</ref>. It affects both men and women; however, CRPS is 3 times more frequent in females than males <ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2211%22])">11</ref>. The number of reported CRPS cases among <weblink xlink:type="simple" xlink:href="http://rsds.org/2/fact_fiction/index.html">
adolescents and young adults is increasing</weblink>. </p>
<p>

Investigators estimate that 2-5 percent of those with peripheral nerve injury <ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2211%22])">11</ref> and 13-70 percent of those with hemiplegia (paralysis of one side of the body) <ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2213%22])">13</ref> will suffer from CRPS.</p>

</sec>
<sec>
<st>
Symptoms</st>
<p>

The symptoms of CRPS usually manifest near the site of an injury, either major or minor, and usually spread beyond the original area.  Symptoms may spread to involve the entire limb and, rarely, the opposite limb. The most common symptom is burning pain. The patient may also experience muscle spasms, local swelling, increased sweating, softening of bones, joint tenderness or stiffness, restricted or painful movement, and changes in the nails and skin.  </p>
<p>

The pain of CRPS is continuous and may be heightened by emotional stress.  Moving or touching the limb is often intolerable.  Eventually the joints become stiff from disuse, and the skin, <link xlink:type="simple" xlink:href="../734/19723734.xml">
muscle</link>s, and bone atrophy.  The symptoms of CRPS vary in severity and duration.  There are three variants of CRPS, previously thought of as stages. It is now believed that patients with CRPS do not progress through these stages sequentially and/or that these stages are not time-limited. Instead, patients are likely to have one of the three following types of disease progression:</p>
<p>

<list>
<entry level="1" type="number">

 Type one is characterized by severe, burning pain at the site of the injury.  Muscle spasm, joint stiffness, restricted mobility, rapid <link xlink:type="simple" xlink:href="../313/14313.xml">
hair</link> and <link xlink:type="simple" xlink:href="../986/397986.xml">
nail</link> growth, and <link xlink:type="simple" xlink:href="../054/1368054.xml">
vasospasm</link> (a constriction of the <link xlink:type="simple" xlink:href="../530/48530.xml">
blood vessel</link>s) that affects color and temperature of the skin can also occur.</entry>
<entry level="1" type="number">

 Type two is characterized by more intense pain.  Swelling spreads, hair growth diminishes, nails become cracked, brittle, grooved, and spotty, <link xlink:type="simple" xlink:href="../461/22461.xml">
osteoporosis</link> becomes severe and diffuse, joints thicken, and muscles atrophy.</entry>
<entry level="1" type="number">

 Type three is characterized by irreversible changes in the skin and bones, while the pain becomes unyielding and may involve the entire limb.  There is marked muscle atrophy, severely limited mobility of the affected area, and flexor <link xlink:type="simple" xlink:href="../865/144865.xml">
tendon</link> contractions (contractions of the muscles and tendons that flex the joints).  Occasionally the limb is displaced from its normal position, and marked bone softening is more dispersed</entry>
</list>
</p>

</sec>
<sec>
<st>
Diagnosis</st>
<p>

CRPS types I and II share the common diagnostic criteria shown below. 
<list>
<entry level="1" type="number">

 Spontaneous pain or <link xlink:type="simple" xlink:href="../030/3339030.xml">
allodynia</link>/<link xlink:type="simple" xlink:href="../355/1021355.xml">
hyperalgesia</link> is not limited to the territory of a single peripheral nerve, and is disproportionate to the inciting event.</entry>
<entry level="1" type="number">

 There is a history of <link xlink:type="simple" xlink:href="../426/70426.xml">
edema</link>, skin blood flow abnormality, or abnormal sweating in the region of the pain since the inciting event.</entry>
<entry level="1" type="number">

 No other conditions can account for the degree of pain and dysfunction.</entry>
</list>
</p>
<p>

The two types differ only in the nature of the inciting event. Type I CRPS develops following an initiating noxious event that may or may not have been traumatic, while type II CRPS develops after a nerve injury. </p>
<p>

No specific test is available for CRPS, which is diagnosed primarily through observation of the symptoms. However, thermography, sweat testing, x-rays, electrodiagnostics, and sympathetic blocks can be used to build up a picture of the disorder. Diagnosis is complicated by the fact that some patients improve without treatment.  A delay in diagnosis and/or treatment for this syndrome can result in severe physical and psychological problems.  Early recognition and prompt treatment provide the greatest opportunity for recovery. </p>

<ss1>
<st>
Thermography</st>
<p>

<link xlink:type="simple" xlink:href="../437/314437.xml">
Thermography</link> is a diagnostic technique for measuring blood flow by determining the variations in heat emitted from the body.  A color-coded "thermogram" of a person in pain often shows an altered blood supply to the painful area, appearing as a different shade (abnormally pale or violet) than the surrounding areas of the corresponding part on the other side of the body.  A difference of 1.0°C between two symmetrical body parts is considered significant, especially if a large number of asymmetrical skin temperature sites are present.  The affected limb may be warmer or cooler than the unaffected limb.</p>

</ss1>
<ss1>
<st>
Sweat testing</st>
<p>

Abnormal sweating can be detected by several tests. A powder that changes color when exposed to sweat can be applied to the limbs; however, this method does not allow for quantification of sweating. Two quantitative tests that may be used are the <link>
resting sweat output test</link> and the <link>
quantitative sudomotor axon reflex test</link>. These quantitative sweat tests have been shown to correlate with clinical signs of CRPS.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2214%22])">14</ref></p>

</ss1>
<ss1>
<st>
Radiography</st>
<p>

Patchy osteoporosis, which may be due to disuse of the affected extremity, can be detected through X-ray imagery as early as two weeks after the onset of CRPS. A <link xlink:type="simple" xlink:href="../576/2671576.xml">
bone scan</link> of the affected limb may detect these changes even sooner. <link xlink:type="simple" xlink:href="../691/377691.xml">
Bone densitometry</link> can also be used to detect changes in bone mineral density. It can also be used to monitor the results of treatment, as bone densitometry parameters improve with treatment.</p>

</ss1>
<ss1>
<st>
Electrodiagnostic testing</st>
<p>

The nerve injury that characterizes type II CRPS can be detected by <link xlink:type="simple" xlink:href="../173/997173.xml">
electromyography</link>. In contrast to <link>
peripheral mononeuropathy</link>, the symptoms of type 2 CRPS extend beyond the distribution of the affected peripheral nerve.</p>

</ss1>
</sec>
<sec>
<st>
Prevention</st>
<p>

Vitamin C has been shown to reduce the prevalence of complex regional pain syndrome after wrist fractures. A daily dose of 500 mg for fifty days is recommended<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2215%22])">15</ref>.</p>

</sec>
<sec>
<st>
Treatment</st>
<p>

The general strategy in CRPS treatment is often multi-disciplinary, with the use of different types of medications combined with distinct physical therapies.  </p>
<p>

Physicians use a variety of drugs to treat CRPS, including <link xlink:type="simple" xlink:href="../ury/24th_century.xml">
antidepressants</link>, anti-inflammatories such as <link xlink:type="simple" xlink:href="../996/57996.xml">
corticosteroids</link> and <link xlink:type="simple" xlink:href="../628/321628.xml">
COX-inhibitors</link> such as <link xlink:type="simple" xlink:href="../087/1426087.xml">
piroxicam</link>, <link xlink:type="simple" xlink:href="../413/479413.xml">
vasodilators</link>, <link xlink:type="simple" xlink:href="../541/184541.xml">
GABA</link> analogs such <link xlink:type="simple" xlink:href="../534/482534.xml">
gabapentin</link> and <link xlink:type="simple" xlink:href="../149/2245149.xml">
pregabalin</link>, and <link xlink:type="simple" xlink:href="../667/18484667.xml">
alpha</link>- or <link xlink:type="simple" xlink:href="../150/180150.xml">
beta-adrenergic-blocking</link> compounds.  </p>
<p>

Elevation of the extremity and physical/occupational therapy are also used to treat CRPS. </p>
<p>

Injection of a local <link xlink:type="simple" xlink:href="../561/56561.xml">
anesthetic</link> such as <link xlink:type="simple" xlink:href="../762/298762.xml">
lidocaine</link> is often the first step in treatment.  Injections are repeated as needed. However, early intervention with non-invasive management may be preferred to repeated nerve blockade.  The use of topical lidocaine patches has been shown to be of use in the treatment of CRPS-1 and -2. <ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2216%22])">16</ref> <ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2217%22])">17</ref></p>
<p>

Neurostimulation (spinal cord stimulators) may also be surgically implanted to reduce the pain by directly stimulating the spinal cord. These devices place electrodes either in the epidural space (space above the spinal cord) or directly over nerves located outside the central nervous system. Implantable drug pumps may also be used to deliver pain medication directly to the cerebrospinal fluid which allows powerful <link xlink:type="simple" xlink:href="../394/511394.xml">
opioid</link>s to be used in a much smaller dose than when taken orally. </p>
<p>

Surgical, chemical, or radiofrequency sympathectomy &mdash; interruption of the affected portion of the sympathetic nervous system &mdash; can be used as a last resort in patients with impending tissue loss, edema, recurrent infection, or ischemic necrosis.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2218%22])">18</ref>  However, there is little evidence that these permanent interventions alter the pain symptoms of the affected patients.</p>
<p>

Physical therapy is the most important part of treatment, though it should be noted that many patients are incapable of participating in physical therapy due to muscular and bone problems. People struggling with CRPS often develop guarding behaviors where they avoid using or touching the affected limb. Unfortunately, inactivity exacerbates the disease and perpetuate the pain cycle. Physical therapy works best for most patients, especially goal-directed therapy, where the patient begins from an initial point, regardless of how minimal, and then endeavors to increase activity each week. Therapy should be directed at facilitating the patient to engage in physical therapy, movement and stimulation of the affected areas.  </p>
<p>

Some treating physicians have even initiated physical therapy under light general anesthesia, in an attempt to remobilize the extremity.  While the unpredictability of this illness often causes a frustrating pattern of progress and regress. Such remobilization can be very dangerous too, if bone and tissue damage has already occurred. It should only be used with extreme caution.</p>
<p>

A study in 2007 indicated that <link>
Collateral Meridian Therapy</link><ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2219%22])">19</ref> was effective in lowering CRPS patient's VAS pain score.</p>
<p>

<link xlink:type="simple" xlink:href="../370/510370.xml">
EEG Biofeedback</link><ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2220%22])">20</ref>, various forms of <link xlink:type="simple" xlink:href="../931/24931.xml">
psychotherapy</link><ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2221%22])">21</ref>, <link xlink:type="simple" xlink:href="../058/1837058.xml">
relaxation techniques</link> and <link xlink:type="simple" xlink:href="../417/14417.xml">
hypnosis</link> <ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2222%22])">22</ref> are adjunctive treatments which assist coping.  </p>
<p>

Acupuncture is an alternative therapy that is gaining popularity for CRPS treatment. </p>

<ss1>
<st>
Ketamine Therapy</st>
<p>

<link xlink:type="simple" xlink:href="../948/16948.xml">
Ketamine</link>, a potent anesthetic, is being used as an experimental and controversial treatment for Complex Regional Pain Syndrome.  The theory of ketamine use in CRPS/RPS is primarily advanced by <link xlink:type="simple" xlink:href="../226/21226.xml">
neurologist</link> Dr Robert J. Schwartzman of <university wordnetid="108286163" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../256/8256.xml">
Drexel University</link></university>
 College of Medicine in Philadelphia, and researchers at the <link>
University of Tübingen</link> in Germany, but was first introduced in the United States by Doctor Ronald Harbut of Little Rock Arkansas. Doctor Harbut and Doctor Graeme Correll (of Queensland, Australia) first began studying the use of ketamine in the treatment of CRPS patients. Dr Harbut's first CRPS patients in the USA were successfully treated in 2002 with the low-dose ketamine infusion; also called the "Awake Technique" and he soon began work with FDA on an approved protocol. In early 2003 Dr Harbut began sharing his treatment methods with the Doctors at Drexel University College of Medicine, including Doctor Schwartzman. The hypothesis is that ketamine manipulates <link xlink:type="simple" xlink:href="../325/374325.xml">
NMDA</link> receptors which might reboot aberrant brain activity. </p>
<p>

In an article discussing Ketamine Infusion Therapy in PAIN MEDICINE, September 2004, it states, "Although ketamine may have more than one mechanism of action, the basis for using it to treat CRPS may reside in its strong ability to block NMDA receptors. Experimental evidence suggests that a sufficiently intense or prolonged painful stimulus causes an extraordinary release of glutamate from peripheral nociceptive afferents onto dorsal horn neurons within the spinal cord. The glutamate released, in turn, stimulates NMDA receptors on second-order neurons that produce the phenomena of windup and central sensitization. It is reasonable to consider that, by blocking NMDA receptors, one might also be able to block cellular mechanisms supporting windup and central sensitization [4–7,15]. Ketamine is the only potent NMDA-blocking drug currently available for clinical use. Our interpretation is that an appropriately prolonged infusion of ketamine appears to maintain a level of ketamine in the central nervous system long enough to reverse the effects of the sensitization process and associated pain." You can read the article in its entirety by going to http://www.blackwell-synergy.com/links/doi/10.1111/j.1526-4637.2004.04043.x/full/?cookieSet=1</p>
<p>

There are two treatment modalities; the first consist of a low dose subanesetheisa Ketamine infusion of between 10-90 mg per hour over several treatment days, this can be delivered in hospital or as an outpatient in some cases. This is called the awake or subanesetheisa technique.</p>
<p>

One promising study located at http://www.blackwell-synergy.com/doi/abs/10.1111/j.1526-4637.2004.04043.x demonstrated that 83% of the patients that participated had complete relief and many others had some relief of the symptoms.  </p>
<p>

Another open label, prospective, pain journal evaluation of a 10-day infusion of intravenous ketamine (awake technique) in the CRPS patient concluded that "A four-hour ketamine infusion escalated from 40-80 mg over a 10-day period can result in a significant reduction of pain with increased mobility and a tendency to decreased autonomic dysregulation".<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2223%22])">23</ref>  </p>
<p>

The second treatment modality consists of putting the patient into a medically-induced <link xlink:type="simple" xlink:href="../721/5721.xml">
coma</link>, then administering an extremely high dosage of ketamine; typically between 600-900 mg.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2224%22])">24</ref> This version, currently not allowed in the United States, is most commonly done in Germany but some treatments are now also taking place in <link>
Monterrey, Nuevo León</link>, <body wordnetid="107965085" confidence="0.8">
<social_group wordnetid="107950920" confidence="0.8">
<political_orientation wordnetid="106212839" confidence="0.8">
<colony wordnetid="108374049" confidence="0.8">
<state wordnetid="108168978" confidence="0.8">
<political_unit wordnetid="108359949" confidence="0.8">
<group wordnetid="100031264" confidence="0.8">
<democracy wordnetid="106217103" confidence="0.8">
<link xlink:type="simple" xlink:href="../054/3966054.xml">
Mexico</link></democracy>
</group>
</political_unit>
</state>
</colony>
</political_orientation>
</social_group>
</body>
.</p>
<p>

According to Dr Schwartzman, 14 cases out of 41 patients in the induced-coma ketamine experiments were completely cured. "We haven't cured the original injury," he says, "but we have cured the RSD or kept it in remission. The RSD pain is gone."</p>
<p>

"No one ever cured it before," he adds. "In 40 years, I have never seen anything like it. These are people who were disabled and in horrible pain. Most were completely incapacitated. They go back to work, back to school, and are doing everything they used to do. Most are on no medications at all. I have taken morphine pumps out of people. You turn off the pain and reset the whole system." <ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2225%22])">25</ref></p>
<p>

No trials have been done for the coma induced method to date.</p>
<p>

This method gained attention in pop culture through season 3 of the FOX television drama <it><link xlink:type="simple" xlink:href="../596/1273596.xml">
House, M.D.</link></it>, which opens a few months after the title character, <fictional_character wordnetid="109587565" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../947/3402947.xml">
Gregory House</link></fictional_character>
, was placed into a ketamine coma to treat ongoing neuropathy in his right leg.  House is shown to have recovered significant use of his right leg (he even goes running regularly), but the treatment eventually wears off and House is once more left in pain and significantly disabled.</p>

</ss1>
</sec>
<sec>
<st>
RSD/CRPS Treatment Centre</st>
<p>

In 2008, Anthony F. Kirkpatrick, MD, PhD, established the RSD/CRPS Treatment Center and Research Institute, the world's first institute of its kind, dedicated exclusively to the diagnosis and treament of RSD/CRPS. The treatment Centre is located in Tampa, Florida. The clinic places particular focus on patient education, and novel, research based therapies not currently found in other treatment facilities. Further information can be found at www.rsdhealthcare.org/index.html#</p>

</sec>
<sec>
<st>
Prognosis</st>
<p>

Good progress can be made in treating CRPS if treatment is begun early, ideally within 3 months of the first symptoms.  If treatment is delayed, however, the disorder can quickly spread to the entire limb and changes in bone, nerve and muscle may become irreversible. The prognosis is not always good. The limb, or limbs, can experience muscle atrophy, loss of use and functionally useless parameters that require amputation. RSD/CRPS will not "burn itself out" but, if treated early, it is likely to go into remission.
http://findarticles.com/p/articles/mi_qa3898/is_200011/ai_n8906623</p>

</sec>
<sec>
<st>
Similar disorders</st>
<p>

CRPS has characteristics similar to those of other disorders, such as <link>
shoulder-hand syndrome</link>, which sometimes occurs after a heart attack and is marked by pain and stiffness in the arm and shoulder; <link>
Sudeck syndrome</link>, which is prevalent in older people and women and is characterized by bone changes and <link>
muscular atrophy</link>, but is not always associated with trauma; and <link>
Steinbrocker syndrome</link>, which includes symptoms such as gradual stiffness, discomfort, and weakness in the shoulder and hand. <link xlink:type="simple" xlink:href="../501/853501.xml">
Erythromelalgia</link> also shares many components of CRPS (burning pain, redness, temperature hypersensitivity, autonomic dysfunction, vasospasm)they both involve small fiber sensory neurosympathetic components. Interestingly Erythromelalgia involves a lack of sweating, whereas CRPS often involves increased sweating. Subvariations of both exist.</p>

</sec>
<sec>
<st>
Current research</st>
<p>

The <link xlink:type="simple" xlink:href="../641/237641.xml">
National Institute of Neurological Disorders and Stroke</link> (NINDS), a part of the National Institutes of Health (NIH), supports and conducts research on the brain and central nervous system, including research relevant to RSDS, through grants to major medical institutions across the country.  NINDS-supported scientists are working to develop effective treatments for neurological conditions and, ultimately, to find ways of preventing them.Investigators are studying new approaches to treat RSDS and intervene more aggressively after traumatic injury to lower the patient's chances of developing the disorder.  In addition, NINDS-supported scientists are studying how signals of the sympathetic nervous system cause pain in RSDS patients.  Using a technique called <link xlink:type="simple" xlink:href="../700/7360700.xml">
microneurography</link>, these investigators are able to record and measure neural activity in single <link xlink:type="simple" xlink:href="../958/958.xml">
nerve fiber</link>s of affected patients.  By testing various hypotheses, these researchers hope to discover the unique mechanism that causes the spontaneous pain of RSDS and that discovery may lead to new ways of blocking pain.Other studies to overcome chronic pain syndromes are discussed in the pamphlet "Chronic Pain:  Hope Through Research," published by the NINDS.</p>
<p>

Research into treating the condition with Mirror Visual Feedback is being undertaken at the Royal National Hospital for Rheumatic Disease in Bath. Patients are taught how to desensitize in the most affective way then progress on to using mirrors to rewrite the faulty signals in the brain that appear responsible for this condition.</p>

</sec>
<sec>
<st>
CRPS in animals</st>
<p>

CRPS has also been described in non-human animals.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2226%22])">26</ref></p>

</sec>
<sec>
<st>
External links</st>
<p>

<list>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://rsdsa.org">
RSDSA</weblink></entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.childhoodrnd.org">
 Childhood RND</weblink></entry>
<entry level="1" type="bullet">

 Power-Through-Pain-Living-With-Neurovascular-Dystrophy</entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://groups.google.com/group/rsdteenparents">
Parents of teens with RND</weblink></entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.rsdhope.org">
RSDhope.org</weblink></entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.forgrace.org">
ForGrace.org</weblink></entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.rsdsupport.com">
http://www.rsdsupport.com</weblink></entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.ninds.nih.gov/health_and_medical/pubs/rsds_fact_sheet.htm">
RSDS Fact Sheet</weblink> at <link xlink:type="simple" xlink:href="../641/237641.xml">
NINDS</link></entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.ninds.nih.gov/disorders/reflex_sympathetic_dystrophy/reflex_sympathetic_dystrophy.htm">
Complex Regional</weblink> at <link xlink:type="simple" xlink:href="../641/237641.xml">
NINDS</link></entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.canadianrsd.com/">
Canadian RSD</weblink></entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.rsd-crps.co.uk">
RSD UK, National charity helping those with and treating the condition</weblink></entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.hollywoodcureforpain.com/">
Celebrity movement for RSD</weblink></entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://RSDtherapy.com">
RSD Therapy</weblink></entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://FightingAgainstRSD.tripod.com">
Fighting Against RSD</weblink></entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.raceagainstpain.com">
Race Against Pain</weblink></entry>
</list>
</p>

</sec>
<sec>
<st>
References</st>

<p>

<reflist>
<entry id="1">
 <cite style="font-style:normal">Richards RL&#32;(1967).&#32;"The Term 'Causalgia'". <it>Medical History</it>&#32;<b>11</b>: 86–90.</cite>&nbsp;</entry>
<entry id="2">
 <cite style="font-style:normal">Evans JA&#32;(1946).&#32;"Reflex sympathetic dystrophy". <it>Surg Clin North America</it>&#32;<b>26</b>: 780–90.</cite>&nbsp;</entry>
<entry id="3">
 <cite style="font-style:normal">Stanton-Hicks M, Janig W, Hassenbusch S, Haddox JD, Boas R, Wilson P&#32;(1995).&#32;"Reflex sympathetic dystrophy: changing concepts and taxonomy". <it>Pain</it>&#32;<b>63</b>&#32;(1): 127–33. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1016%2F0304-3959%2895%2900110-E">
10.1016/0304-3959(95)00110-E</weblink>. PMID 8577483.</cite>&nbsp;</entry>
<entry id="4">
 <cite style="font-style:normal">Correll GE, Maleki J, Gracely EJ, Muir JJ, Harbut RE&#32;(2004).&#32;"Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome". <it>Pain Med</it>&#32;<b>5</b>&#32;(3): 263–75. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1111%2Fj.1526-4637.2004.04043.x">
10.1111/j.1526-4637.2004.04043.x</weblink>. PMID 15367304.</cite>&nbsp;
</entry>
<entry id="5">
 <cite style="font-style:normal">Kiefer RT, Rohr P, Ploppa A, et al&#32;(2008).&#32;"A pilot open-label study of the efficacy of subanesthetic isomeric S(+)-ketamine in refractory CRPS patients". <it>Pain Med</it>&#32;<b>9</b>&#32;(1): 44–54. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1111%2Fj.1526-4637.2006.00223.x">
10.1111/j.1526-4637.2006.00223.x</weblink>. PMID 18254766.</cite>&nbsp;
</entry>
<entry id="6">
 <cite style="font-style:normal">Pöyhiä R, Vainio A&#32;(2006).&#32;"<weblink xlink:type="simple" xlink:href="http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00002508-200601000-00005">
Topically administered ketamine reduces capsaicin-evoked mechanical hyperalgesia</weblink>". <it>Clin J Pain</it>&#32;<b>22</b>&#32;(1): 32–6. PMID 16340591.</cite>&nbsp;</entry>
<entry id="7">
 <cite style="font-style:normal">Watkins LR, Maier SF&#32;(2005).&#32;"Immune regulation of central nervous system functions: from sickness responses to pathological pain". <it>J. Intern. Med.</it>&#32;<b>257</b>&#32;(2): 139–55. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1111%2Fj.1365-2796.2004.01443.x">
10.1111/j.1365-2796.2004.01443.x</weblink>. PMID 15656873.</cite>&nbsp;
</entry>
<entry id="8">
 <cite style="font-style:normal">Koffler SP, Hampstead BM, Irani F, et al&#32;(2007).&#32;"The neurocognitive effects of 5 day anesthetic ketamine for the treatment of refractory complex regional pain syndrome". <it>Arch Clin Neuropsychol</it>&#32;<b>22</b>&#32;(6): 719–29. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1016%2Fj.acn.2007.05.005">
10.1016/j.acn.2007.05.005</weblink>. PMID 17611073.</cite>&nbsp;
</entry>
<entry id="9">
 <cite style="font-style:normal">Birklein F&#32;(2005).&#32;"Complex regional pain syndrome". <it>J. Neurol.</it>&#32;<b>252</b>&#32;(2): 131–8. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1007%2Fs00415-005-0737-8">
10.1007/s00415-005-0737-8</weblink>. PMID 15729516.</cite>&nbsp;
</entry>
<entry id="10">
 <cite style="font-style:normal">Zollinger PE, Tuinebreijer WE, Breederveld RS, Kreis RW&#32;(2007).&#32;"Can Vitamin C Prevent Complex Regional Pain Syndrome in Patients with Wrist Fractures? A Randomized, Controlled, Multicenter Dose-Response Study". <it>J Bone Joint Surg Am</it>&#32;<b>89</b>&#32;(7): 1424–1431. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.2106%2FJBJS.F.01147">
10.2106/JBJS.F.01147</weblink>. PMID 17606778.</cite>&nbsp;</entry>
<entry id="11">
 <cite style="font-style:normal">Veldman PH, Reynen HM, Arntz IE, Goris RJ&#32;(1993).&#32;"<weblink xlink:type="simple" xlink:href="http://linkinghub.elsevier.com/retrieve/pii/0140-6736(93)92877-V">
Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients</weblink>". <it>Lancet</it>&#32;<b>342</b>&#32;(8878): 1012–6. PMID 8105263.</cite>&nbsp;</entry>
<entry id="12">
 <cite style="font-style:normal">Güler-Uysal F, Başaran S, Geertzen JH, Göncü K&#32;(2003).&#32;"<weblink xlink:type="simple" xlink:href="http://cre.sagepub.com/cgi/pmidlookup?view=long&amp;pmid=12625665">
A 2 1/2-year-old girl with reflex sympathetic dystrophy syndrome (CRPS type I): case report</weblink>". <it>Clin Rehabil</it>&#32;<b>17</b>&#32;(2): 224–7. PMID 12625665.</cite>&nbsp;</entry>
<entry id="13">
 <cite style="font-style:normal">Yu D&#32;(August 2004).&#32;"Shoulder pain in hemiplegia". <it>Phys Med Rehabil Clin N Am</it>&#32;<b>15</b>&#32;(3): vi–vii, 683–97. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1016%2FS1047-9651%2803%2900130-X">
10.1016/S1047-9651(03)00130-X</weblink>. PMID 15219895.</cite>&nbsp;</entry>
<entry id="14">
 <cite style="font-style:normal">Sandroni P, Low PA, Ferrer T, Opfer-Gehrking TL, Willner CL, Wilson PR&#32;(1998).&#32;"Complex regional pain syndrome I (CRPS I): prospective study and laboratory evaluation". <it>Clin J Pain</it>&#32;<b>14</b>&#32;(4): 282–9. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1097%2F00002508-199812000-00003">
10.1097/00002508-199812000-00003</weblink>. PMID 9874005.</cite>&nbsp;</entry>
<entry id="15">
 <cite style="font-style:normal">Zollinger PE, Tuinebreijer WE, Breederveld RS, Kreis RW.&#32;(2007).&#32;"Can vitamin C prevent complex regional pain syndrome in patients with wrist fractures? A randomized, controlled, multicenter dose-response study.". <it>The Journal of Bone and Joint Surgery.  American volume.</it>&#32;<b>89</b>: 1424&ndash;31. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.2106%2FJBJS.F.01147">
10.2106/JBJS.F.01147</weblink>. PMID 17606778.</cite>&nbsp;</entry>
<entry id="17">
 <cite style="font-style:normal">Frost, SG.&#32;(2003).&#32;"Treatment of Complex Regional Pain Syndrome Type 1 in a Pediatric Patient Using the Lidocaine Patch 5%: A Case Report.". <it>Current Therapeutic Research</it>&#32;<b>64</b>&#32;(8): 626–9. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1016%2Fj.curtheres.2003.09.010">
10.1016/j.curtheres.2003.09.010</weblink>.</cite>&nbsp;</entry>
<entry id="16">
 <cite style="font-style:normal">Devers A, Galer BS&#32;(2000).&#32;"<weblink xlink:type="simple" xlink:href="http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0749-8047&amp;volume=16&amp;issue=3&amp;spage=205">
Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study</weblink>". <it>Clin J Pain</it>&#32;<b>16</b>&#32;(3): 205–8. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1097%2F00002508-200009000-00005">
10.1097/00002508-200009000-00005</weblink>. PMID 11014393.</cite>&nbsp;</entry>
<entry id="19">
 <cite style="font-style:normal">Wong CS, Kuo CP, Fan YM, Ko SC&#32;(2007).&#32;"<weblink xlink:type="simple" xlink:href="http://www.anesthesia-analgesia.org/cgi/content/citation/104/2/452">
Collateral meridian therapy dramatically attenuates pain and improves functional activity of a patient with complex regional pain syndrome</weblink>". <it>Anesth. Analg.</it>&#32;<b>104</b>&#32;(2): 452. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1213%2F01.ane.0000247767.10131.35">
10.1213/01.ane.0000247767.10131.35</weblink>. PMID 17242110.</cite>&nbsp;</entry>
<entry id="18">
 <cite style="font-style:normal">Stanton-Hicks M, Baron R, Boas R, Gordh T, Harden N, Hendler N, Koltzenburg M, Raj P, Wilder R&#32;(1998).&#32;"Complex Regional Pain Syndromes: guidelines for therapy". <it>Clin J Pain</it>&#32;<b>14</b>&#32;(2): 155–66. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1097%2F00002508-199806000-00012">
10.1097/00002508-199806000-00012</weblink>. PMID 9647459.</cite>&nbsp;</entry>
<entry id="21">
<weblink xlink:type="simple" xlink:href="http://www.rsmpsychology.com/rsd.htm">
http://www.rsmpsychology.com/rsd.htm</weblink>The Psychologist's Role in the Chronic Pain of Reflex Sympathetic Dystrophy. Rosemarie Scolaro Moser, Ph.D. Printed in New Jersey Psychologist, Spring 1999. Pages 24-25. </entry>
<entry id="20">
<weblink xlink:type="simple" xlink:href="http://www.rsds.org/5/news/2005/biofeedback.htm">
http://www.rsds.org/5/news/2005/biofeedback.htm</weblink>webpage references:  <cite style="font-style:normal">Grunert BK, Devine CA, Sanger JR, Matloub HS, Green D&#32;(1990).&#32;"Thermal self-regulation for pain control in reflex sympathetic dystrophy syndrome". <it>J Hand Surg [Am]</it>&#32;<b>15</b>&#32;(4): 615–8. PMID 2199569.</cite>&nbsp;</entry>
<entry id="23">
 <cite style="font-style:normal">Goldberg ME, Domsky R, Scaringe D, et al&#32;(2005).&#32;"<weblink xlink:type="simple" xlink:href="http://www.painphysicianjournal.com/linkout_vw.php?issn=1533-3159&amp;vol=8&amp;page=175">
Multi-day low dose ketamine infusion for the treatment of complex regional pain syndrome</weblink>". <it>Pain Physician</it>&#32;<b>8</b>&#32;(2): 175–9. PMID 16850072.</cite>&nbsp;</entry>
<entry id="22">
 <cite style="font-style:normal">Gainer MJ&#32;(1992).&#32;"Hypnotherapy for reflex sympathetic dystrophy". <it>Am J Clin Hypn</it>&#32;<b>34</b>&#32;(4): 227–32. PMID 1349789.</cite>&nbsp;</entry>
<entry id="25">
<weblink xlink:type="simple" xlink:href="http://www.ketamine.com/antidepressant-potential.html">
http://www.ketamine.com/antidepressant-potential.html</weblink>Szalavitz, Maia. "Tackling depression with ketamine", New Scientist, January 20, 2007.</entry>
<entry id="24">
<weblink xlink:type="simple" xlink:href="http://www.rsdfoundation.org/en/CNN_Transcript_RSD.htm">
http://www.rsdfoundation.org/en/CNN_Transcript_RSD.htm</weblink> CNN report on Ketamine therapy for CRPS/RSD September 1, 2006</entry>
<entry id="26">
 <cite style="font-style:normal">Bergadano A, Moens Y, Schatzmann U&#32;(2006).&#32;"Continuous extradural analgesia in a cow with complex regional pain syndrome". <it>Vet Anaesth Analg</it>&#32;<b>33</b>&#32;(3): 189–92. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1111%2Fj.1467-2995.2005.00245.x">
10.1111/j.1467-2995.2005.00245.x</weblink>. PMID 16634945.</cite>&nbsp;</entry>
</reflist>
</p>

<p>

<table style=";" class="navbox" cellspacing="0">
<row>
<col style="padding:2px;">
<table style="width:100%;background:transparent;color:inherit;;" class="nowraplinks collapsible autocollapse " cellspacing="0">
<row>
<header colspan="2" style=";background: Silver;" class="navbox-title">
<link xlink:type="simple" xlink:href="../944/21944.xml">
Nervous system</link> <link xlink:type="simple" xlink:href="../791/48791.xml">
pathology</link>, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../317/608317.xml">
primarily PNS</link></disease>
 (, )</header>
</row>
<row style="height:2px;">

</row>
<row>
<col style=";background-color: LightYellow;" class="navbox-group">
<link xlink:type="simple" xlink:href="../435/21435.xml">
Nerve</link>, nerve root
and <link xlink:type="simple" xlink:href="../073/103073.xml">
plexus</link>disorders</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<table style="width:100%;;;;" class="nowraplinks  navbox-subgroup" cellspacing="0">
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../721/18327721.xml">
Cranial nerve disease</link></disease>
</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<it>V</it> (<link xlink:type="simple" xlink:href="../890/311890.xml">
Trigeminal neuralgia</link>) - <it>VII</it> (<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../559/1256559.xml">
Facial nerve paralysis</link></disease>
, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../957/52957.xml">
Bell's palsy</link></disease>
, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../598/3730598.xml">
Melkersson-Rosenthal syndrome</link></disease>
, <link xlink:type="simple" xlink:href="../333/8511333.xml">
Central seven</link>) - <it>XI</it> (<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../970/12423970.xml">
Accessory nerve disorder</link></disease>
)</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../835/8639835.xml">
Radiculopathy</link></disease>
, <link xlink:type="simple" xlink:href="../102/16081102.xml">
plexopathy</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../352/13085352.xml">
Brachial plexus lesion</link></disease>
 - <link xlink:type="simple" xlink:href="../166/759166.xml">
Thoracic outlet syndrome</link> - <link xlink:type="simple" xlink:href="../877/325877.xml">
Phantom limb</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
<link xlink:type="simple" xlink:href="../703/3064703.xml">
Mono-</link> <link xlink:type="simple" xlink:href="../514/56514.xml">
neuropathy</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<it>upper limb</it> (<link xlink:type="simple" xlink:href="../462/56462.xml">
Carpal tunnel syndrome</link>, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../899/11266899.xml">
Ulnar nerve entrapment</link></disease>
, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../200/4896200.xml">
Radial neuropathy</link></disease>
)<p>

<it>lower limb</it> (<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../206/3019206.xml">
Meralgia paraesthetica</link></disease>
, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../974/2632974.xml">
Tarsal tunnel syndrome</link></disease>
, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../406/3087406.xml">
Morton's neuroma</link></disease>
) </p>
<p>

<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../283/56283.xml">
Causalgia</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../979/4167979.xml">
Mononeuritis multiplex</link></disease>
</p>
</col>
</row>
</table>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";background-color: LightYellow;" class="navbox-group">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../862/797862.xml">
Polyneuropathies</link></disease>
</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<table style="width:100%;;;;" class="nowraplinks  navbox-subgroup" cellspacing="0">
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
<link xlink:type="simple" xlink:href="../947/17595947.xml">
HMSN</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../845/7845.xml">
Charcot-Marie-Tooth disease</link> - <link xlink:type="simple" xlink:href="../669/5882669.xml">
Dejerine Sottas syndrome</link> - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../915/4681915.xml">
Refsum's disease</link></disease>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../796/11636796.xml">
Polyradiculoneuropathy</link></disease>
</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<it><link xlink:type="simple" xlink:href="../842/93842.xml">
autoimmune</link></it> (<link>
Guillain-Barré syndrome</link>, <link xlink:type="simple" xlink:href="../404/4666404.xml">
Chronic inflammatory demyelinating polyneuropathy</link>) - <link xlink:type="simple" xlink:href="../821/1205821.xml">
Alcoholic polyneuropathy</link></col>
</row>
</table>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";background-color: LightYellow;" class="navbox-group">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../499/17397499.xml">
Diseases of muscle</link></disease>
 (<link xlink:type="simple" xlink:href="../683/1531683.xml">
myopathy</link>)/
<link xlink:type="simple" xlink:href="../565/4543565.xml">
neuromuscular disease</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<table style="width:100%;;;;" class="nowraplinks  navbox-subgroup" cellspacing="0">
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../609/18327609.xml">
Neuromuscular junction disease</link></disease>
</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<it><link xlink:type="simple" xlink:href="../842/93842.xml">
autoimmune</link></it> (<link xlink:type="simple" xlink:href="../998/18998.xml">
Myasthenia gravis</link>, <link xlink:type="simple" xlink:href="../628/18628.xml">
Lambert-Eaton myasthenic syndrome</link>)</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
<link xlink:type="simple" xlink:href="../982/18982.xml">
Muscular dystrophy</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../459/5144459.xml">
Congenital</link></disease>
 - <it><link xlink:type="simple" xlink:href="../316/940316.xml">
dystrophin</link></it> (<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../404/1024404.xml">
Becker's</link></disease>
, <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../284/974284.xml">
Duchenne</link></disease>
) - <link xlink:type="simple" xlink:href="../175/6043175.xml">
Distal</link> - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../486/5679486.xml">
Emery-Dreifuss</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../824/2570824.xml">
Facioscapulohumeral</link></disease>
 - <link xlink:type="simple" xlink:href="../452/399452.xml">
Limb-girdle muscular dystrophy</link> - <link xlink:type="simple" xlink:href="../508/8276508.xml">
Myotonic</link> - <link xlink:type="simple" xlink:href="../516/1039516.xml">
Oculopharyngeal</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
<link xlink:type="simple" xlink:href="../692/411692.xml">
Myotonia</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../508/8276508.xml">
Myotonic dystrophy</link> - <link xlink:type="simple" xlink:href="../601/2775601.xml">
Myotonia congenita</link> - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../804/3242804.xml">
Thomsen disease</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../221/21221.xml">
Neuromyotonia</link></disease>
 - <link xlink:type="simple" xlink:href="../603/3360603.xml">
Paramyotonia congenita</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../504/9078504.xml">
Congenital myopathy</link></disease>
</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<link xlink:type="simple" xlink:href="../916/9348916.xml">
Bethlem myopathy</link> - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../836/16613836.xml">
Central core disease</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../443/4960443.xml">
Centronuclear myopathy</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../228/1900228.xml">
Nemaline myopathy</link></disease>
 - <link xlink:type="simple" xlink:href="../367/4029367.xml">
Zaspopathy</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../614/2858614.xml">
Mitochondrial myopathy</link></disease>
</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../191/3713191.xml">
MELAS</link> - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../696/5788696.xml">
MERRF</link></disease>
 - <link xlink:type="simple" xlink:href="../700/3021700.xml">
KSS</link> - <link xlink:type="simple" xlink:href="../843/2973843.xml">
PEO</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../309/2936309.xml">
Periodic paralysis</link></disease>
</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../547/3360547.xml">
Hypokalemic</link></disease>
 - <link xlink:type="simple" xlink:href="../881/1017881.xml">
Hyperkalemic</link></col>
</row>
</table>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";background-color: LightYellow;" class="navbox-group">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../746/410746.xml">
Dysautonomia</link></disease>
/
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../918/249918.xml">
Autonomic neuropathy</link></disease>
</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../014/17596014.xml">
HSAN</link> (<message wordnetid="106598915" confidence="0.8">
<disorder wordnetid="114052403" confidence="0.8">
<condition wordnetid="113920835" confidence="0.8">
<subject wordnetid="106599788" confidence="0.8">
<state wordnetid="100024720" confidence="0.8">
<physical_condition wordnetid="114034177" confidence="0.8">
<link xlink:type="simple" xlink:href="../545/1212545.xml">
Familial dysautonomia</link></physical_condition>
</state>
</subject>
</condition>
</disorder>
</message>
) - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../251/1340251.xml">
Horner's syndrome</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../802/861802.xml">
Multiple system atrophy</link></disease>
 (<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../316/317316.xml">
Shy-Drager syndrome</link></disease>
, <link xlink:type="simple" xlink:href="../995/1283995.xml">
Olivopontocerebellar atrophy</link>)</col>
</row>
</table>
</col>
</row>
</table>
</p>

<p>

<table style=";" class="navbox" cellspacing="0">
<row>
<col style="padding:2px;">
<table style="width:100%;background:transparent;color:inherit;;" class="nowraplinks collapsible autocollapse " cellspacing="0">
<row>
<header colspan="2" style=";background:Silver" class="navbox-title">
<link xlink:type="simple" xlink:href="../388/3221388.xml">
Osteochondropathy</link> (, )</header>
</row>
<row style="height:2px;">

</row>
<row>
<col style=";background-color: WhiteSmoke;" class="navbox-group">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../617/12116617.xml">
Osteopathies</link></disease>
</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../605/3578605.xml">
Osteitis</link> (<link xlink:type="simple" xlink:href="../272/3163272.xml">
Osteitis fibrosa cystica</link>)<p>

<it>disorders of <link xlink:type="simple" xlink:href="../186/5791186.xml">
bone density</link> and structure:</it> <link xlink:type="simple" xlink:href="../461/22461.xml">
Osteoporosis</link> - <sign wordnetid="106646243" confidence="0.8">
<indication wordnetid="106797169" confidence="0.8">
<evidence wordnetid="106643408" confidence="0.8">
<clue wordnetid="106643763" confidence="0.8">
<link xlink:type="simple" xlink:href="../083/2236083.xml">
Osteopenia</link></clue>
</evidence>
</indication>
</sign>
 - <link xlink:type="simple" xlink:href="../985/545985.xml">
Osteomalacia</link> </p>
<p>

<it>continuity of bone:</it> (<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../666/1827666.xml">
Pseudarthrosis</link></disease>
, <link xlink:type="simple" xlink:href="../689/1173689.xml">
Stress fracture</link>) - <disorder wordnetid="114052403" confidence="0.8">
<condition wordnetid="113920835" confidence="0.8">
<state wordnetid="100024720" confidence="0.8">
<physical_condition wordnetid="114034177" confidence="0.8">
<link xlink:type="simple" xlink:href="../101/1617101.xml">
Fibrous dysplasia</link></physical_condition>
</state>
</condition>
</disorder>
 (<link xlink:type="simple" xlink:href="../321/12356321.xml">
Monostotic fibrous dysplasia</link>) - <pathological_state wordnetid="114051917" confidence="0.8">
<condition wordnetid="113920835" confidence="0.8">
<state wordnetid="100024720" confidence="0.8">
<physical_condition wordnetid="114034177" confidence="0.8">
<ill_health wordnetid="114052046" confidence="0.8">
<link xlink:type="simple" xlink:href="../069/323069.xml">
Skeletal fluorosis</link></ill_health>
</physical_condition>
</state>
</condition>
</pathological_state>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../049/5884049.xml">
Aneurysmal bone cyst</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../073/5830073.xml">
Hyperostosis</link></disease>
 - <link xlink:type="simple" xlink:href="../094/526094.xml">
Osteosclerosis</link></p>
<p>

<it><link xlink:type="simple" xlink:href="../147/3230147.xml">
bone resorption</link>:</it> <link xlink:type="simple" xlink:href="../240/1969240.xml">
Osteolysis</link> - <link xlink:type="simple" xlink:href="../900/4469900.xml">
Hajdu-Cheney syndrome</link> - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../653/1025653.xml">
Ainhum</link></disease>
</p>
<p>

<it>other:</it> <link xlink:type="simple" xlink:href="../094/595094.xml">
Osteomyelitis</link> - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../676/1498676.xml">
Avascular necrosis</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../007/650007.xml">
Paget's disease of bone</link></disease>
 - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../283/56283.xml">
Algoneurodystrophy</link></disease>
 - <link xlink:type="simple" xlink:href="../552/4292552.xml">
Infantile cortical hyperostosis</link></p>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";background-color: WhiteSmoke;" class="navbox-group">
<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../371/2920371.xml">
Chondropathies</link></disease>
</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<link xlink:type="simple" xlink:href="../590/1403590.xml">
Chondritis</link> (<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../401/2684401.xml">
Relapsing polychondritis</link></disease>
)<p>

<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../445/317445.xml">
Tietze's syndrome</link></disease>
</p>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";background-color: WhiteSmoke;" class="navbox-group">
Both</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../620/3105620.xml">
Osteochondritis</link> (<link xlink:type="simple" xlink:href="../029/3762029.xml">
Osteochondritis dissecans</link>)<it><link xlink:type="simple" xlink:href="../291/2477291.xml">
Juvenile osteochondrosis</link>:</it> <link>
Legg–Calvé–Perthes syndrome</link> -  <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../874/1720874.xml">
Osgood-Schlatter disease</link></disease>
 - <disorder wordnetid="114052403" confidence="0.8">
<condition wordnetid="113920835" confidence="0.8">
<state wordnetid="100024720" confidence="0.8">
<physical_condition wordnetid="114034177" confidence="0.8">
<link xlink:type="simple" xlink:href="../198/8089198.xml">
Blount's disease</link></physical_condition>
</state>
</condition>
</disorder>
 - <link>
Köhler disease</link> - <disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../526/3104526.xml">
Sever's disease</link></disease>
 - <bone wordnetid="105269901" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../203/1585203.xml">
Kienbock's disease</link></bone>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col colspan="2" style="width:100%;padding:0px;;;" class="navbox-list navbox-even">
<it>see also , ''</it></col>
</row>
</table>
</col>
</row>
</table>
</p>


</sec>
</bdy>
</disease>
</article>
